Adult T-cell leukemia-lymphoma (ATL) is a T-cell malignancy caused by human T-cell leukemia virus type 1 (HTLV-1) [1, 2] . ATL is classified into four clinical subtypes proposed by the Japan Clinical Oncology Group: smoldering, chronic, lymphoma, and acute [1] . Acute-and lymphoma-type ATL have a poor prognosis. Allogeneic hematopoietic stem cell transplantation (allo-SCT) is being increasingly used as a curative therapy for ATL, and confers long-term survival in approximately 40% of ATL patients [2] . One of the major problems of allo-SCT is occurrence of severe complications. We observed ATL patients who developed peripheral neuropathy (PN) following allo-SCT. In this study, we analyzed their disease profiles and investigated the pathophysiology of PN.
We investigated the clinical features of 46 ATL patients who underwent allo-SCT after induction chemotherapy. The study consisted of 25 men and 21 women aged 28-71 (median age: 59) years. The ATL clinical subtypes observed in these patients included 33 (72%), 8 (17%), and 5 (11%) with the acute-, lymphoma-, and unfavorable chronic-types, respectively. Conditioning regimens consisting of myeloablative conditioning (MAC) and reduced intensity conditioning (RIC) were administered to 5 (11%) and 41 (89%) of the patients, respectively. Stem cell sources included the bone marrow for 35 (77%) of the cases, peripheral blood in 10 (21%), and cord blood in 1 (2%). PN was diagnosed by the symptoms of paresthesia, hyperesthesia, abnormal sensations, and muscle weakness. This included damage to sensory and motor nerves with axonal and/or demyelinating damage. We performed a full neurological examination, a nerve conduction study (motor or sensory conduction), as well as radiological procedures such as computed tomography and/or magnetic resonance imaging (MRI). We also performed cell counts, evaluated cerebrospinal fluid (CSF) biochemistry, and measured total protein levels, anti-HTLV-1 antibody titers, neopterin, and CXCL10 levels in CSF.
Three patients developed PN after allo-SCT. Profiles and CSF data of these patients are shown in Table 1 . All patients had an Eastern Cooperative Oncology Group performance status (ECOG-PS) of grade 3 or 4. They achieved and maintained complete remission after allo-SCT; however, they developed acute graft-versus-host disease (aGVHD) and/or chronic graft-versus-host disease (cGVHD) involving multiple organs.
Patient 1 was a 57-year-old man who underwent allo-SCT. He had lymphoma-type ATL and achieved partial remission (PR) after induction chemotherapy. He received a human leukocyte antigen (HLA) 8/8 allele-matched unrelated bone marrow transplantation. Within a month after transplantation, he developed an abnormal sensation below the epigastrium, hypoesthesia, muscle weakness in the lower limbs, and absence of a tendon reflex. Concurrently, he also developed skin aGVHD (grade I). A nerve conduction study revealed no electrical conduction on the left median, fibular, and tibial nerves.
Patient 2 was a 60-year-old man who underwent allo-SCT. He was diagnosed with lymphoma-type ATL and achieved PR after induction chemotherapy. He received an HLA 8/8 matched unrelated peripheral blood stem cell transplantation (PBSCT). After 11 months, he developed lower limb-dominant muscle weakness, and sensory loss. He simultaneously developed cGVHD in his eyes, mouth, skin, and lungs. A nerve conduction study showed disappearance of electrical conduction on both sides of the peroneal and sural nerves.
Patient 3 was a 68-year-old woman who underwent allo-SCT. She had acute-type ATL and achieved PR after induction chemotherapy. She received an HLA 8/8 matched related PBSCT. She subsequently developed muscle weakness in her bilateral extremities after seven years. In addition, she developed hypoesthesia of the lower limb, and cGVHD in her eyes, mouth, skin, lungs, liver, and muscles. A nerve conduction study revealed absence of electrical conduction in the bilateral cervical nerve.
CSF anti-HTLV-1 antibody results were negative in two of these patients, while these results were weakly positive in the third patient who demonstrated a four-fold increase in the CSF anti-HTLV-1 titer levels. All patients showed albuminocytologic dissociation in their CSF. CSF cerebrospinal fluid, PN peripheral neuropathy, SCT stem cell transplantation, ATL adult T-cell leukemia-lymphoma, HTLV-1 human T-cell leukemia virus type 1, BU busulfan, CyA cyclosporine A, DS disease status, PR partial remission FLU fludarabine, BM bone marrow, PB peripheral blood, HLA human leukocyte antigen, MAC myeloablative conditioning, MMF mycophenolate mofetil, MTX methotrexate, RIC reduced intensity conditioning, Tac tacrolimus, TBI total body irradiation, aGVHD acute graft-versus-host disease, cGVHD chronic graft-versus-host disease, N/A not available a Below the detection limit
All the three patients' symptoms persisted for more than 2 months, and diffuse demyelination of peripheral nerves was confirmed via a nerve conduction study. CSF examinations showed albuminocytologic dissociation, as mentioned earlier.
According to the diagnostic criteria (European Federation of Neurological Societies/Peripheral Nerve Society guidelines), all three patients met the chronic inflammatory demyelinating polyneuropathy (CIDP) criteria [3] .
Some reports showed Guillain-Barre syndrome following allo-SCT [4] [5] [6] . However, Guillain-Barre syndrome was considered unlikely because of the absence of cranial nerve or respiratory muscle paralysis and autonomic dysfunction. In addition, prior infection usually found in Guillain-Barre syndrome was not present in all the patients. Although a previous report suggested that the onset of symptoms occurred immediately during the post-transplant period [5] , the same was not observed in our patients. Two patients were found not to have any anti-GM antibody, a frequent finding in Guillain-Barre syndrome.
In HTLV-1-infected patients, it is important to consider human T-cell leukemia virus 1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) in a differential diagnosis. As the deep tendon reflexes were reduced, and a pathological reflex was not apparent in these patients, results suggested that they did not have myelopathy. Based on the lack of myelopathy and CSF data, HAM/TSP was ruled out.
There was no increase in the number of cells in the CSF, and no mass lesion in the brain was detected using radiological procedures. ATL relapse in the central nervous system (CNS) was not considered.
Hence, we initiated the appropriate CIDP treatment, including corticosteroids, intravenous immunoglobulin, and plasmapheresis [7] [8] [9] [10] . However, neither the corticosteroids nor the intravenous immunoglobulin was effective.
Previous studies have described neuropathy (including CIDP) following allo-SCT for various hematological diseases (Table 2) [6, [8] [9] [10] [11] ; however, to date the same has not been reported in ATL patients undergoing allo-SCT. To the best of our knowledge, this is the first report of CIDP in ATL patients who received allo-SCT.
The onset of CIDP in two patients occurred immediately after the onset of aGVHD or cGVHD. This suggests that CIDP may be one of the symptoms of GVHD. To support this, previous studies have reported of infiltrations of either CD4-or CD8-positive cells in nerve biopsy specimens obtained from patients with CIDP related to allo-SCT as histopathological evidence of GVHD in the peripheral nervous system [8, 10] . Although our patients preferred treatment intervention and did not undergo neurological biopsy, it may be beneficial to consider a biopsy. Other previous reports showed that cGVHD was associated with loss of selftolerance and that its manifestation resembled an autoimmune disease. This suggests that cGVHD causes immune dysregulation and predisposes patients to develop CIDP following SCT [9] . A previous report investigating the incidence and characteristics of the peripheral nervous system manifestations occurring after allo-SCT in patients with hematological disease [12] found an association between RIC and PBSCT with specific peripheral nerve damage. In our study, all patients underwent RIC, and two of them underwent PBSCT.
Neopterin is a small molecule derived from guanosine triphosphate that is produced by macrophages and microglia. CXCL10 is an inflammatory chemokine that binds to CXCR3, expressed specifically on Th1 cells, and is produced by astrocytes. Neopterin and CXCL10 levels are reported to be elevated in the CSF of patients with neuroinflammatory disorders such as HAM/TSP and multiple sclerosis [13] , and are indicators of CNS inflammation [14] . The expression of both neopterin and CXCL10 is stimulated AML acute myeloid leukemia, ALL acute lymphoblastic leukemia, MDS myelodysplastic syndromes, CML chronic myelogenous leukemia, NHL non-Hodgkin's lymphoma, HL Hodgkin's lymphoma, AA aplastic anemia, ATL adult T-cell leukemia-lymphoma, PN peripheral neuropathy, CIDP chronic inflammatory demyelinating polyneuropathy, SCT stem cell transplantation, M male, F female, d day, w week, m month, y year, BM bone marrow, CB cord blood, PB peripheral blood, R recovery, PR partial recovery, D death, U unchanged, N/A not available by interferon-γ (IFN-γ) produced by T cells. Because all of our patients did not have HAM/TSP and CNS relapse of ATL, it was considered to be a nonspecific reaction. One of hypothesis is that aberrantly activated donor T cells produce IFN-γ, which leads to the elevation of the neopterin and CXCL10 levels. Thus, CIDP and GVHD seem to have similar mechanisms involving activated T cells. Drug-induced CIDP cannot be completely ruled out. For example, tacrolimus has been reported to induce CIDP in patients who received liver transplantation [15] . Although our two patients were receiving tacrolimus, the onset of CIDP in our patients was much later than that observed in other case reports.
No structural disorder was detected on the MRI scans of the spinal cord, vertebrae, and discs in patients 1 and 2. Patient 3 had cervical spondylosis which was thought to be one of the causes of PN. However, subsequent findings, including the elevation of CXCL10 in CSF, indicated the possibility of other causes of PN in patient 3. Vincristine (VCR) was administered to all patients at induction chemotherapy before allo-SCT. If the cause of neuropathy is VCR, the neuropathy usually recovers after discontinuation of administration. However, it did not recover and VCR may not be main reason. None of them had diabetes mellitus, and diabetic neuropathy was not considered. Vitamin B 12 levels in patients 1 and 2 were in the normal range. In patient 3, vitamin B 12 was not checked; however, there were no history or background characteristics that could be regarded as a risk for vitamin B 12 deficiency.
Transplant physicians should be aware of these clinical features in ATL patients. Further study is warranted to reveal the relationship between ATL and PN following allo-SCT and the underlying mechanism.
